Leads Biolabs submits China NDA for opamtistomig in advanced EP

Leads Biolabs filed a New Drug Application (NDA) with China's National Medical Products Administration (NMPA) for opamtistomig (LBL-024) for the treatment of advanced extrapulmonary neuroendocrine carcinoma. The submission is supported by data from a Phase IIb monotherapy study in patients who had previously undergone at least two systemic regimens.